Literature DB >> 34023776

The H3K4 methyltransferase SETD1A is required for proliferation of non-small cell lung cancer cells by promoting S-phase progression.

Joo-Young Kang1, Jin Woo Park1, Yusang Hwang1, Ja Young Hahm1, Junyoung Park1, Kwon-Sik Park2, Sang-Beom Seo3.   

Abstract

Epigenetic dysregulation has been strongly implicated in carcinogenesis and is one of the mechanisms that contribute to the development of lung cancer. Using genome-wide CRISPR/Cas9 library screening, we showed SET domain-containing protein 1A (SETD1A) is an essential epigenetic modifier of the proliferation of NSCLC H1299 cells. Depletion of SETD1A strikingly inhibited the proliferation of NSCLC cells. IHC staining and bioinformatics showed that SETD1A is upregulated in lung cancer. Kaplan-Meier survival analysis indicated that high expression of SETD1A is associated with poor prognosis of patients with NSCLC. We revealed that loss of SETD1A inhibits DNA replication and induces replication stress accompanied by impaired fork progression. In addition, transcription of CDC7 and TOP1, which are involved in replication origin activation and fork progression, respectively, was significantly reduced by knockdown of SETD1A. Taken together, these findings demonstrated SETD1A is a critical epigenetic modifier of NSCLC cell proliferation by promoting the transcription of a subset of DNA replication-associated genes.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR screen; H3K4me3; Non-small cell lung cancer; Replication; SETD1A

Year:  2021        PMID: 34023776     DOI: 10.1016/j.bbrc.2021.05.026

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer.

Authors:  Hai Yang; Bin Liu; Dongxue Liu; Zhirong Yang; Shuman Zhang; Pengyan Xu; Yuming Xing; Isabella Kutschick; Susanne Pfeffer; Nathalie Britzen-Laurent; Robert Grützmann; Christian Pilarsky
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.